Compass Therapeutics Inc.

Compass Therapeutics announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, its ongoing Phase II/III trial with tovecimig (formerly CTX-009) in combinati

Two of the largest biopharmaceutical initial public offerings in the US this year – both by companies headquartered outside of the US – were among the latest batch of IPOs. Evotec SE ’s $435m offerin

Three biopharma firms were scheduled to launch initial public offerings during the week of 9-13 November but all three postponed or delayed their offerings, raising the question of whether the booming

Indoor dining at restaurants and bars is shutting down again as the COVID-19 pandemic worsens in the US as numbers of confirmed cases of the novel coronavirus reach new daily highs, and most companies